(NewsDirect)
Pharmaxis Ltd (ASX:PXS) CEO Gary Phillips tells Proactive thecompany will add a combination treatment arm to the current Phase 2clinical trial of PXS?5505 in myelofibrosis following helpfulfeedback from the US FDA. He says they’re already in discussion withthe existing trial site investigators who have welcomed theopportunity to extend the patient population for the study andanticipate significantly accelerated recruitment.
ContactDetails
Proactive Investors
JonathanJackson
+61 413 713 744
jonathan@proactiveinvestors.com
Copyright (c) 2023 TheNewswire - All rights reserved.